登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 3
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
- 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
- 研究中心中南大学湘雅三医院Third Xiangya Hospital长沙医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05768529,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Women of childbearing potential must have a negative blood/urine pregnancy test within 7 days before U16 cell infusion; any male or female trial participant of reproductive potential must agree to use effective contraceptive methods throughout the entire study and for at least one year after administration of the study treatment;
入选标准第 10 条
Use of immunosuppressants, high-dose chemotherapy within 2 weeks before signing the informed consent form, or use of hormones within 3 days, or planned requirement for immunosuppressants or hormones after signing the informed consent form and before/after apheresis; specifically referring to systemic therapy, excluding local or inhaled corticosteroid therapy;
排除标准第 3 条
Trial participants who have previously received CD20-targeted CAR-T therapy;
排除标准第 10 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
入选标准第 7 条
According to the Lugano classification for lymphoma response assessment (Cheson 2014), at least 1 CT-measurable lesion (for nodal lesions: defined as long axis >1.5 cm; for extranodal lesions: long axis should be >1.0 cm), and a lesion confirmed positive by PET-CT;
入选标准第 6 条
Concurrent other malignancies, except for malignancies with disease-free survival exceeding 3 years and carcinoma in situ;
排除标准第 1 条
History of immunodeficiency, including human immunodeficiency virus (HIV) infection; positive anti-Treponema pallidum antibody (TP-Ab); hepatitis B virus infection (hepatitis B surface antigen [HBsAg] positive and hepatitis B virus deoxyribonucleic acid [HBV-DNA] quantification > lower limit of detection); hepatitis C virus infection (hepatitis C virus [HCV] antibody positive and hepatitis C virus ribonucleic acid [HCV-RNA] quantification > lower limit of detection);
排除标准第 4 条
Pregnant or breastfeeding women;
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05768529,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Trial participants voluntarily sign the informed consent form and have good compliance; Age ≥18 years and ≤70 years at the time of signing the informed consent form; male or female trial participants are eligible; Indication: B-cell non-Hodgkin lymphoma that is CD20-positive as demonstrated by immunohistochemistry (IHC) staining of prior tumor tissue samples or by bone marrow cells, and consistent with the 2017 WHO classification of NHL, including: diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) to large B-cell lymphoma, and high-grade B-cell lymphoma (HGBCL); Prior treatment with ≥2 lines of adequate therapy or autologous hematopoietic stem cell transplantation (ASCT). Adequate therapy includes: a) Must have received adequate treatment including anthracyclines and rituximab or other CD20-targeted agents (except for CD20-negative tumors); b) Lines of therapy: best response to first-line treatment was progressive disease (PD), or best response to at least 4 cycles of first-line treatment was stable disease (SD), or best response to at least 6 cycles of first-line treatment was PR; PD again during/after the last line of treatment (second-line or beyond), or best response to at least 2 cycles of the last line of treatment was SD. c) For TFL to large B-cell lymphoma: prior to transformation, the participant must have received adequate treatment for FL, and has relapsed or is refractory during/after the last line of treatment after transformation; if the initial diagnosis is transformed lymphoma, the participant must have received ≥2 lines of therapy and has relapsed or is refractory during/after the last line of treatment; In a state of disease relapse or refractoriness at screening: a) Definition of relapse: PD again after achieving response (including partial response (PR) or complete response (CR)) following adequate treatment; b) Definition of refractoriness: i. No response to the last treatment: PD during/after the last treatment or best response of SD with a duration of less than 6 months; ii. Relapse or progression after ASCT (confirmed by biopsy), including: relapse or PD within 12 months after ASCT; if salvage therapy was subsequently received, no response to the last treatment (SD or PD); According to the Lugano classification for lymphoma response assessment (Cheson 2014), at least 1 CT-measurable lesion (for nodal lesions: defined as long axis >1.5 cm; for extranodal lesions: long axis should be >1.0 cm), and a lesion confirmed positive by PET-CT; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; Adequate bone marrow reserve at screening, defined as: absolute neutrophil count (ANC) ≥ 1.0×10⁹/L, absolute lymphocyte count (ALC) ≥ 0.3×10⁹/L, platelet count (PLT) ≥ 50×10⁹/L; Adequate organ function, meeting the following criteria: aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN); alanine aminotransferase (ALT) ≤3× ULN (for hepatic function abnormalities due to tumor infiltration, AST and ALT ≤5× ULN are required); total serum bilirubin ≤2× ULN, unless accompanied by Gilbert syndrome; trial participants with Gilbert syndrome who have total bilirubin ≤3× ULN and direct bilirubin ≤1.5× ULN may be enrolled. Serum creatinine ≤1.5× ULN, or creatinine clearance ≥60 mL/min (Cockcroft and Gault formula); minimum pulmonary reserve, defined as dyspnea ≤ grade 1 and oxygen saturation >91% without supplemental oxygen; Women of childbearing potential must have a negative blood/urine pregnancy test within 7 days before U16 cell infusion; any male or female trial participant of reproductive potential must agree to use effective contraceptive methods throughout the entire study and for at least one year after administration of the study treatment; Adequate venous access for apheresis or venous blood collection, and no other contraindications to leukapheresis; Washout period for CD20-targeted agents of at least 6 weeks before screening (applicable to trial participants who have received rituximab or other CD20-targeted agents); Expected survival greater than 3 months.排除标准:Exclusion Criteria:
Concurrent other malignancies, except for malignancies with disease-free survival exceeding 3 years and carcinoma in situ; Trial participants with lymphoma infiltration of the cardiac atria or ventricles; Use of immunosuppressants, high-dose chemotherapy within 2 weeks before signing the informed consent form, or use of hormones within 3 days, or planned requirement for immunosuppressants or hormones after signing the informed consent form and before/after apheresis; specifically referring to systemic therapy, excluding local or inhaled corticosteroid therapy; History of immunodeficiency, including human immunodeficiency virus (HIV) infection; positive anti-Treponema pallidum antibody (TP-Ab); hepatitis B virus infection (hepatitis B surface antigen [HBsAg] positive and hepatitis B virus deoxyribonucleic acid [HBV-DNA] quantification > lower limit of detection); hepatitis C virus infection (hepatitis C virus [HCV] antibody positive and hepatitis C virus ribonucleic acid [HCV-RNA] quantification > lower limit of detection); Presence of bacterial, fungal, viral, mycoplasma, or other types of infection that the investigator judges to be difficult to control; Presence of active primary or secondary central nervous system (CNS) lymphoma at screening (trial participants with symptoms of CNS disease must undergo lumbar puncture to rule out CNS lymphoma); Prior or current clinically significant CNS disease, such as seizures, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any CNS-related autoimmune disease; Coronary angioplasty or stent placement within 12 months before signing the informed consent form, or myocardial infarction, unstable angina pectoris, or other clinically significant cardiac history as judged by the investigator; severe arrhythmia requiring treatment; left ventricular ejection fraction (LVEF) ≤50%; hypertension inadequately controlled despite standard treatment (systolic ≥160 mmHg and/or diastolic ≥100 mmHg) or pulmonary arterial hypertension; Trial participants with clinical emergencies requiring urgent management due to lymphoma tumor mass obstruction or compression as judged by the investigator (such as intestinal obstruction or vascular compression, etc.); Trial participants who have previously received CD20-targeted CAR-T therapy; History of severe immediate hypersensitivity reaction to any drug to be used in this study; Receipt of live vaccine within 6 weeks before screening; Pregnant or breastfeeding women; Active autoimmune disease; Presence of active acute or chronic graft-versus-host disease (GVHD) at the time of signing the informed consent form; Receipt of allogeneic hematopoietic stem cell transplantation within 6 months before signing the informed consent form; Any concomitant disease that may affect or interfere with the assessment of safety or efficacy; Presence of active deep vein thrombosis (tumor thrombus or thrombosis) or pulmonary embolism within 3 months before signing the ICF; however, if the investigator judges that the thrombosis has been clinically managed and there is no risk of dislodgement, enrollment is permitted; Any condition deemed by the investigator as unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT05768529, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05768529,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。